![Enlivex Therapeutics Ltd](/common/images/company/N_ENLV.png)
Enlivex Therapeutics Ltd (ENLV)
NASDAQ
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -102.883 | -24.829 | -41.237 | -65.636 | -40.83 | -21.354 | -38.16 | -55.647 |
Return on Equity (%) | -120.326 | -29.13 | -46.618 | -89.423 | -50.563 | -24.008 | -43.783 | -66.881 |
Return on Invested Capital (%) | -120.908 | -25.338 | -58.588 | -82.736 | -42.004 | -32.162 | -36.596 | -58.473 |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | 0.513 | 2.054 | 1.016 | 0.711 | 1.764 | 3.565 | 2.374 | 1.247 |
Earnings Per Share | -0.945 | -0.641 | -0.47 | -0.592 | -0.588 | -0.606 | -1.297 | -1.205 |
Cash Per Share | 0.405 | 2.304 | 1.078 | 0.344 | 0.34 | 0.47 | 2.086 | 0.034 |
Working Capital Per Share | 0.508 | 2.154 | 1.013 | 0.658 | 1.678 | 3.426 | 1.909 | 1.148 |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | -0.932 | -0.641 | -0.47 | -0.592 | -0.588 | -0.606 | -1.297 | -1.205 |
EBITDA Per Share | -0.932 | -0.641 | -0.47 | -0.592 | -0.588 | -0.606 | -1.297 | -1.205 |
Free Cash Flow Per Share | -0.945 | -0.629 | -0.432 | -0.593 | -0.551 | -0.561 | -0.99 | -1.23 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 16,39M | 3,34M | 3,51M | 10,33M | 14,59M | 18,33M | 18,42M | 18,6M |
Fin d'année 31 Décembre 2023 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | 18,42M | 18,57M | 18,59M | 18,6M | 18,6M | 18,81M | 20,88M | 21,99M |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Net Profit Margin (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 21,72M |
Ratio cours/bénéfice | -0,75 |
Ratio prix/ventes | 0 |
Ratio prix/liquidités | 26,99 |
Ratio prix/valeur comptable | 0,73 |
Rendement de dividende | - |
Actions en circulation | 20,88M |
Volume moyen (1 semaine) | 40,4k |
Volume moyen (1 mois) | 49,77k |
Variation sur 52 semaines | -66,24% |
Plus haut sur 52 semaines | 4,59 |
Plus bas sur 52 semaines | 0,8101 |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales